# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
2024 Guidance LifeStance is providing the following outlook for 2024: The Company is reiterating full year revenue of $1.19...
2024 Guidance LifeStance is providing the following outlook for 2024: The Company is reiterating full year revenue of $1.19...
LifeStance Health Gr (NASDAQ:LFST) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of ...
Lifeist Wellness' Q1 2024 financial results, highlight a strategic shift towards higher-margin products and improved effici...
Morgan Stanley analyst Ricky Goldwasser reiterates LifeStance Health Gr (NASDAQ:LFST) with a Overweight and maintains $10 pr...
Lifeist Wellness Inc. reported on Monday its financial results for the three and 12 months ended Nov. 30, 2023. The Toronto-bas...
Jefferies analyst Brian Tanquilut maintains LifeStance Health Gr (NASDAQ:LFST) with a Buy and raises the price target from $...
Goldman Sachs analyst Jamie Perse maintains LifeStance Health Gr (NASDAQ:LFST) with a Neutral and raises the price target fr...